In our study, we found no consistent trends in prostate cancer risk according to duration of GLP-1RA use, whereas the Clinical Practice Research Datalink study reported a reduced risk of prostate cancer with 2 years of GLP-1RA use, but no clear trend with increasing duration of use [5]
However, no clear pattern was found across treatment days
Our luxury health retreat in Doral, Florida, offers a scientifically-backed approach to wellness that can complement your medication regimen
The Phase 2 trial showed 24.2% weight loss at 48 weeks, and Phase 3 data suggests 28.7% at 68 weeks
Regulation of innate immune system function by the microbiome: consequences for tumor immunity and cancer immunotherapy
Saxagliptin Saxagliptin is eliminated by both renal and hepatic pathways